177 related articles for article (PubMed ID: 8223799)
1. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.
Saggese G; Bertelloni S; Baroncelli GI; Battini R; Franchi G
Eur J Pediatr; 1993 Sep; 152(9):717-20. PubMed ID: 8223799
[TBL] [Abstract][Full Text] [Related]
2. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
[TBL] [Abstract][Full Text] [Related]
3. Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion.
Saggese G; Bertelloni S; Baroncelli GI; Pardi D; Cinquanta L
J Endocrinol Invest; 1991 Mar; 14(3):231-6. PubMed ID: 1830057
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
Verrotti A; Chiarelli F; Montanaro AF; Morgese G
Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
[TBL] [Abstract][Full Text] [Related]
6. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
7. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
[TBL] [Abstract][Full Text] [Related]
8. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.
Bertelloni S; Baroncelli GI; Ferdeghini M; Menchini-Fabris F; Saggese G
Eur J Pediatr; 2000 May; 159(5):369-74. PubMed ID: 10834524
[TBL] [Abstract][Full Text] [Related]
9. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
[TBL] [Abstract][Full Text] [Related]
10. [Improvement of expected and final height in girls with central precocious puberty treated with gonadotropin releasing hormone analogues].
Gómez F; Picó AM; Vargas F; Mauri M
Med Clin (Barc); 1996 Nov; 107(18):681-4. PubMed ID: 9082075
[TBL] [Abstract][Full Text] [Related]
11. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist.
Ko JH; Lee HS; Lim JS; Kim SM; Hwang JS
Horm Res Paediatr; 2011; 75(3):174-9. PubMed ID: 20881364
[TBL] [Abstract][Full Text] [Related]
13. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
[TBL] [Abstract][Full Text] [Related]
14. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
15. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Heger S; Partsch CJ; Sippell WG
J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
[TBL] [Abstract][Full Text] [Related]
18. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.
Park HK; Lee HS; Ko JH; Hwang IT; Lim JS; Hwang JS
Clin Endocrinol (Oxf); 2012 Nov; 77(5):743-8. PubMed ID: 22530679
[TBL] [Abstract][Full Text] [Related]
19. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
[TBL] [Abstract][Full Text] [Related]
20. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
